BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Drulovic J, Ivanovic J, Martinovic V, Tamas O, Veselinovic N, Cujic D, Gnjatovic M, Mesaros S, Pekmezovic T. HUMORAL RESPONSE TO SARS-CoV-2 AND COVID-19 VACCINES IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH IMMUNE RECONSTITUTION THERAPIES. Mult Scler Relat Disord 2021;54:103150. [PMID: 34298478 DOI: 10.1016/j.msard.2021.103150] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Bellucci G, Rinaldi V, Buscarinu MC, Reniè R, Bigi R, Pellicciari G, Morena E, Romano C, Marrone A, Mechelli R, Salvetti M, Ristori G. Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started? Front Immunol 2021;12:755333. [PMID: 34646278 DOI: 10.3389/fimmu.2021.755333] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Capone F, Lucchini M, Ferraro E, Bianco A, Rossi M, Cicia A, Cortese A, Cruciani A, De Arcangelis V, De Giglio L, Motolese F, Sancetta B, Mirabella M, Di Lazzaro V. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies. Neurotherapeutics 2021. [PMID: 34859382 DOI: 10.1007/s13311-021-01165-9] [Reference Citation Analysis]
3 Abdellatif AAH, Alsowinea AF. Approved and marketed nanoparticles for disease targeting and applications in COVID-19. Nanotechnology Reviews 2021;10:1941-77. [DOI: 10.1515/ntrev-2021-0115] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Shacham-Shmueli E, Itay A, Margalit O, Berger R, Halperin S, Jurkowicz M, Levin EG, Levy I, Olmer L, Regev-Yochay G, Lustig Y, Rahav G. Letter of response to comment on: Efficacy and safety of BNT162b2 vaccination in solid cancer patients receiving anti-cancer therapy - A single centre prospective study. Eur J Cancer 2022;160:285-6. [PMID: 34840027 DOI: 10.1016/j.ejca.2021.10.019] [Reference Citation Analysis]
5 Galmiche S, Luong Nguyen LB, Tartour E, de Lamballerie X, Wittkop L, Loubet P, Launay O. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clin Microbiol Infect 2021:S1198-743X(21)00566-8. [PMID: 35020589 DOI: 10.1016/j.cmi.2021.09.036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 18.0] [Reference Citation Analysis]
6 Brill L, Rechtman A, Zveik O, Haham N, Levin N, Shifrin A, Rozenberg A, Vaknin-Dembinsky A. Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis. Mult Scler Relat Disord 2022;57:103343. [PMID: 35158452 DOI: 10.1016/j.msard.2021.103343] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, Zheng Q, Li G, Teng Y, Wu M, Song X. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther 2022;7:166. [PMID: 35597779 DOI: 10.1038/s41392-022-01007-w] [Reference Citation Analysis]
8 Etemadifar M, Sedaghat N, Nouri H, Lotfi N, Chitsaz A, Khorvash R, Zolfaghari H, Ghasemi Movaghar A, Pourabbas M, Salari M. SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine. Mult Scler Relat Disord 2021;57:103417. [PMID: 34875487 DOI: 10.1016/j.msard.2021.103417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
9 Jovicevic V, Ivanovic J, Momcilovic N, Andabaka M, Tamas O, Veselinovic N, Cujic D, Gnjatovic M, Mesaros S, Pekmezovic T, Drulovic J. Humoral response to SARS-CoV-2 infection and vaccines against COVID-19 in patients with neuromyelitis optica spectrum disorders: Impact of immunosuppressive treatment. Multiple Sclerosis and Related Disorders 2022;62:103794. [DOI: 10.1016/j.msard.2022.103794] [Reference Citation Analysis]
10 Grothe C, Steffen F, Bittner S. Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets. J Cent Nerv Syst Dis 2021;13:11795735211060118. [PMID: 34880703 DOI: 10.1177/11795735211060118] [Reference Citation Analysis]
11 Giovannoni G, Mathews J. Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review. Neurol Ther 2022;11:571-95. [PMID: 35318617 DOI: 10.1007/s40120-022-00339-7] [Reference Citation Analysis]
12 Moser T, O'Sullivan C, Puttinger C, Feige J, Pilz G, Haschke-Becher E, Cadamuro J, Oberkofler H, Hitzl W, Harrer A, Kraus J, Trinka E, Wipfler P. Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy. Biomedicines 2021;9:1584. [PMID: 34829815 DOI: 10.3390/biomedicines9111584] [Reference Citation Analysis]